Currently, there are 50.14M common shares owned by the public and among those 44.59M shares have been available to trade.
The company’s stock has a 5-day price change of -5.66% and 28.21% over the past three months. GLUE shares are trading -11.50% year to date (YTD), with the 12-month market performance down to -1.38% lower. It has a 12-month low price of $2.44 and touched a high of $8.84 over the same period. GLUE has an average intraday trading volume of 269.57K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.05%, -7.09%, and -6.63% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) shares accounts for 62.23% of the company’s 50.14M shares outstanding.
It has a market capitalization of $306.85M and a beta (3y monthly) value of 1.43. The earnings-per-share (ttm) stands at -$2.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.18% over the week and 8.96% over the month.
Earnings per share for the fiscal year are expected to increase by 27.69%, and 3.77% over the next financial year.
Looking at the support for the GLUE, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on February 15, 2024, with the firm’s price target at $11. Wells Fargo coverage for the Monte Rosa Therapeutics Inc (GLUE) stock in a research note released on January 03, 2023 offered a Overweight rating with a price target of $18. UBS was of a view on October 13, 2022 that the stock is Buy, while Jefferies gave the stock Buy rating on August 15, 2022, issuing a price target of $20. Credit Suisse on their part issued Neutral rating on April 28, 2022.
